Literature DB >> 1456411

Cord blood IgE. II. Prediction of atopic disease. A follow-up at the age of 18 months.

L G Hansen1, A Høst, S Halken, A Holmskov, S Husby, L B Lassen, K Storm, O Osterballe.   

Abstract

Screening of total IgE in 2814 cord blood samples was analysed by Phadebas IgE PRIST in 2 1-year birth cohorts (1983-1984 and 1985-1986) in Denmark (n = 1189 + 1625). For follow-up we chose all infants with cord blood IgE greater than or equal to 0.5 kU/l and a randomly chosen group of the same size with cord blood IgE less than 0.5 kU/l. A total of 762 infants were clinically evaluated at 18 months of age. A diagnosis of definite atopy, probable atopy or no atopy, including both IgE and non-IgE mediated disease was established. Applying different cord blood IgE cut-off values (0.3, 0.5, 0.8, 1.1) we did not find an excess of atopic infants among those with elevated cord blood IgE irrespective of the chosen cut-off value. Atopic predisposition or family history of atopic disease was defined as at least one parent or older sibling with atopic disease. Significantly more infants with a family history developed atopy at 18 months. In the 2 series the positive predictive values of cord blood IgE greater than or equal to 0.5 were 43% and 46% and the sensitivities were 17% and 15%. The predictive values of having a family history were 48% and 44% and the sensitivities were 55% and 58%.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456411     DOI: 10.1111/j.1398-9995.1992.tb02079.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

Review 1.  Immune mechanisms of childhood asthma.

Authors:  C E Donovan; P W Finn
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  The relationship between cord blood immunoglobulin E levels and allergy-related outcomes in young adults.

Authors:  Purvee S Shah; Ganesa Wegienka; Suzanne Havstad; Christine Cole Johnson; Dennis R Ownby; Edward M Zoratti
Journal:  Ann Allergy Asthma Immunol       Date:  2011-01-26       Impact factor: 6.347

3.  Raised cord serum immunoglobulin E increases the risk of allergic sensitisation at ages 4 and 10 and asthma at age 10.

Authors:  A Sadeghnejad; W Karmaus; S Davis; R J Kurukulaaratchy; S Matthews; S H Arshad
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

4.  IgE against food and respiratory allergens in healthy and allergic mothers and their children.

Authors:  L Prokesová; O Novotná; I Janatková; P Zanvit; J Zizka; R Lodinová-Zádníková; I Kocourková; I Sterzl
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.099

5.  Asthma Heredity, Cord Blood IgE and Asthma-Related Symptoms and Medication in Adulthood: A Long-Term Follow-Up in a Swedish Birth Cohort.

Authors:  Hartmut Vogt; Lennart Bråbäck; Olof Zetterström; Katalin Zara; Karin Fälth-Magnusson; Lennart Nilsson
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

6.  Cord blood cellular proliferative response as a predictive factor for atopic dermatitis at 12 months.

Authors:  Hyo-Bin Kim; Kang Mo Ahn; Kyung Won Kim; Youn Ho Shin; Jinho Yu; Ju-Hee Seo; Hyung Young Kim; Ji-Won Kwon; Byoung-Ju Kim; Ja-Young Kwon; Suk-Joo Choi; Kyung-Ju Lee; Hee Jin Park; Hye-Sung Won; Soo-Jong Hong
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

Review 7.  Different implications of paternal and maternal atopy for perinatal IgE production and asthma development.

Authors:  Chih-Chiang Wu; Rong-Fu Chen; Ho-Chang Kuo
Journal:  Clin Dev Immunol       Date:  2012-01-09

8.  Cord blood IgE predicts allergic sensitization, elevation of exhaled nitric oxide, and asthma in schoolchildren.

Authors:  Hsin-Ju Lee; Hui-Ju Tsai; Hsin-Yi Huang; Chun-Chun Gau; Chia-Hua Ho; Jing-Long Huang; Tsung-Chieh Yao
Journal:  Pediatr Allergy Immunol       Date:  2022-08       Impact factor: 5.464

Review 9.  Treatment of eczema.

Authors:  Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 10.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.